Dr. Oz and FDA chief say biosimilar drug reform will lower prices

Trump administration officials pledged Monday that major reforms for biosimilar drug approvals will expand access and lower prices for some of the most expensive drugs on the market. Food and Drug Administration Commissioner Marty Makary and Centers for Medicare and Medicaid Services Administrator Mehmet Oz outlined further details about the Trump administration’s plan to slash [.].